## Review setup
- **Input scope** Full manuscript text (Introduction, Experimental, Results and Discussion, Conclusion) as provided by the user. Supplementary material not available for review.
- **Assessment boundary** Scientific content, technical soundness, internal consistency, and support of claims based solely on the provided text. No external literature verification or replication of experiments performed.
- **Shared manuscript claim summary** The authors report the synthesis and structural characterization of a novel platinum(IV) supramolecular complex, [PtCl2(2,2'-bipy)2](PtCl6), and evaluate its DNA binding, molecular docking interactions, and anticancer activity against three cancer cell lines (HepG2, HCT116, MDA-MB-231) and a normal cell line (MRC5).
- **Visible evidence base** Synthetic procedure, elemental analysis, IR, 1H and 13C NMR, single-crystal X-ray diffraction (crystallographic table, bond lengths/angles, hydrogen bonding and π–π stacking descriptions), UV-vis absorption and emission spectra, DNA binding via absorption titration and viscometry, molecular docking results (tables of scores), and MTT-based cytotoxicity data with IC50 values and selectivity indices.
- **Missing materials affecting confidence** Supplementary figures (Fig. S1–S6) and tables referenced but not provided. Full crystallographic data (CIF file) not available. Docking methodology details (e.g., preparation of the metal complex, charge parameters, validation of docking protocol beyond RMSD) are incomplete. Statistical analysis details for cytotoxicity data (e.g., number of replicates, error bars) are not fully described. No raw spectra or chromatograms provided.

## Reviewer
- **Overall assessment** The manuscript presents a straightforward synthesis and structural characterization of a platinum(IV) complex, with supporting spectroscopic and crystallographic data. The biological experiments are preliminary and descriptive. The DNA binding studies and docking are consistent with each other but the interpretation is limited and the anticancer data are presented without sufficient statistical context. The work is incremental in nature, adding to a large body of literature on platinum complexes with bipyridine ligands. The structural work appears competent, but the biological claims are overstated relative to the evidence provided. The manuscript would benefit from a more rigorous and quantitative treatment of the biological data and a clearer articulation of what is genuinely novel.

- **Who would be interested in the results, and why** Researchers in the field of bioinorganic chemistry, specifically those working on platinum-based anticancer drug candidates, may find the crystallographic and spectroscopic characterization of this specific complex of interest. The DNA binding and docking data may be of interest to computational chemists studying metal complex-nucleic acid interactions. However, the incremental nature of the findings and the lack of mechanistic depth limit the breadth of the audience.

- **Major Strengths**
    - The single-crystal X-ray diffraction analysis appears to be of reasonable quality, with clear presentation of the asymmetric unit, coordination geometry, and supramolecular interactions.
    - The synthetic procedure is simple and reproducible, and the compound is fully characterized by standard techniques (IR, NMR, elemental analysis).
    - The combination of experimental DNA binding studies (absorption and viscometry) with molecular docking provides a consistent, if preliminary, picture of the binding mode.

- **Major Concerns**

    - **Concern ID** R1-M1
    - **Severity** Major
    - **Blocking** Yes
    - **Axis** Technical soundness of biological claims
    - **Claim pointer** The manuscript claims the complex has "anticancer evaluation" and is a "less toxic and more effective as an anticancer agent" based on IC50 values and selectivity indices.
    - **Evidence pointer** Section "Anticancer evaluation of SC 1 on human cancer cell lines", Table 8, Fig. 8, Fig. 9
    - **Concern** The anticancer activity is only assessed via a single MTT assay endpoint after 48 h. The IC50 values are presented without error bars, confidence intervals, or any indication of the number of independent experiments. The comparison to cisplatin is made directly, but no statistical test is reported to establish significance. The claim of "less toxic" is based on a single normal cell line (MRC5) and a calculated SI, which is a very weak basis for such a conclusion. The morphological images (Fig. 9) are qualitative and not quantified.
    - **Why it matters** The central translational claim of the paper is that this complex is a promising, selective anticancer agent. Without proper statistical validation and a more comprehensive cytotoxicity profile (e.g., multiple time points, additional normal cell lines, apoptosis assays), this claim is not supported by the evidence presented. The current data only show that the compound has some cytotoxic effect at micromolar concentrations.
    - **Resolution test** Provide the number of replicates (n) and standard deviations/error bars for all IC50 values. Perform and report a statistical comparison (e.g., t-test or ANOVA) between the IC50 of SC 1 and cisplatin for each cell line. Include a dose-response curve for at least one cell line. If the claim of selectivity is to be maintained, test against at least one additional non-cancerous cell line and report the SI with appropriate error propagation.

    - **Concern ID** R1-M2
    - **Severity** Major
    - **Blocking** Yes
    - **Axis** Technical soundness of DNA binding mode determination
    - **Claim pointer** The manuscript states that "Electronic absorption titration and viscosity measurements indicate groove binding."
    - **Evidence pointer** Section "Studies of DNA binding", Fig. 5
    - **Concern** The determination of the binding mode is based on two indirect methods. The absorption titration shows hyperchromism and a hypsochromic shift, which the authors attribute to groove binding. However, hyperchromism can also be observed in partial intercalation or external binding. The viscometry data are described only in the text as showing "minimal viscosity changes," but the actual plot (Fig. 5, right) is not described in detail, and the raw data are not provided. The conclusion of groove binding is therefore not rigorously established. Furthermore, the binding constant (Kb = 5.00 × 10⁶ M⁻¹) is reported without an error estimate.
    - **Why it matters** The binding mode is a key mechanistic claim of the paper. If the mode is misassigned, the interpretation of the docking results and the overall mechanism of action would be incorrect. The current evidence is suggestive but not definitive.
    - **Resolution test** Provide the full viscometry data plot with error bars. Consider performing a competitive binding assay with a known intercalator (e.g., ethidium bromide) or a groove binder (e.g., Hoechst 33258) to confirm the binding mode. Report the Kb value with a standard error from at least three independent titrations. If possible, perform circular dichroism (CD) spectroscopy to provide more definitive evidence of the binding mode.

    - **Concern ID** R1-M3
    - **Severity** Major
    - **Blocking** No
    - **Axis** Technical soundness of molecular docking
    - **Claim pointer** The manuscript claims that docking results "correlate well with the experimental data, demonstrating strong interactions."
    - **Evidence pointer** Section "Molecular docking of SC 1 and different proteins", Tables 6 and 7, Figs. 6 and 7
    - **Concern** The docking methodology is described in insufficient detail. The preparation of the platinum(IV) complex for docking (e.g., partial charges, coordination geometry, protonation state) is not described. The choice of the target proteins (3ig7, 3eqm, 4fm9) is not justified. The docking scores are presented, but the significance of these scores is not discussed in the context of known inhibitors or other metal complexes. The RMSD values are mentioned but not interpreted. The claim of "correlation" with experimental data is qualitative and not quantified.
    - **Why it matters** Docking is used to support the experimental findings and provide a structural rationale. Without a robust and well-described protocol, the docking results are not reproducible and their validity is questionable. The lack of a quantitative correlation between docking scores and experimental binding affinities weakens the claim of a strong interaction.
    - **Resolution test** Provide a detailed description of the docking protocol, including software settings, charge calculation method, and validation of the docking protocol (e.g., redocking of co-crystallized ligand with acceptable RMSD). Justify the choice of protein targets. If claiming correlation, perform a quantitative analysis (e.g., linear regression) between docking scores and experimental Kb or IC50 values.

- **Minor Comments**

    - **Concern ID** R1-m1
    - **Severity** Minor
    - **Axis** Clarity and consistency
    - **Affected element** Experimental section, "Studies of DNA binding"
    - **Evidence pointer** Section "Studies of DNA binding", subsection "Determination of binding affinities spectroscopically"
    - **Issue** The equation for Kb determination is presented in a non-standard format and the variables are not defined in the text. The description of the viscometry experiment is confusing, with the definitions of η and η₀ appearing to be swapped. The text states "η is the specific viscosity of ct-DNA alone and ηo is the specific viscosity of the ct-DNA-SC 1," which is the opposite of the standard convention.
    - **Required correction** Define all variables in the equation. Correct the definitions of η and η₀ in the viscometry section to match the standard convention (η is the viscosity of the solution with the complex, η₀ is the viscosity of the buffer or DNA alone).

    - **Concern ID** R1-m2
    - **Severity** Minor
    - **Axis** Data presentation
    - **Affected element** Table 8, Fig. 8
    - **Evidence pointer** Section "Anticancer evaluation of SC 1 on human cancer cell lines"
    - **Issue** The concentration range used for the cytotoxicity assay is not stated. The text mentions a range of 6.25–200 µg/mL in one place, but the table reports IC50 values in µM. The conversion is not shown. The figure legend for Fig. 8 does not specify the concentration of SC 1 used for the morphological images.
    - **Required correction** State the concentration range used in the assay in both µg/mL and µM. Show the conversion factor used. Clarify in the Fig. 8 legend the concentration of SC 1 and cisplatin used for the imaging.

    - **Concern ID** R1-m3
    - **Severity** Minor
    - **Axis** Interpretation of spectroscopic data
    - **Affected element** Section "The UV–vis and emission spectra"
    - **Evidence pointer** Table 5, Fig. 4
    - **Issue** The assignment of the emission band at 350 nm to MLCT is speculative without further evidence, such as lifetime measurements or comparison to related complexes. The statement that "The fluorescence intensity of SC 1 is higher than that of the free ligand" is made without a quantitative comparison or explanation of the quantum yield.
    - **Required correction** Provide a more cautious interpretation of the emission spectra. If possible, include quantum yield measurements or cite literature for similar complexes to support the MLCT assignment.

    - **Concern ID** R1-m4
    - **Severity** Minor
    - **Axis** Language and grammar
    - **Affected element** Throughout the manuscript
    - **Evidence pointer** Multiple sections, e.g., Introduction, Results and Discussion
    - **Issue** There are several grammatical errors and awkward phrasings, e.g., "developed resistance to cancer cells" should be "developed resistance in cancer cells," and "a more -ve docking score signifies improved interaction" is informal. The sentence "According to our result, there is any change in viscosity of the DNA with SC 1" is grammatically incorrect and contradicts the intended meaning.
    - **Required correction** The manuscript should be carefully edited for grammar and clarity by a native English speaker.

- **Technical failings that need to be addressed before the case is established**
    - Lack of statistical analysis for all biological data (R1-M1).
    - Insufficient evidence for the definitive assignment of the DNA binding mode (R1-M2).
    - Incomplete description of the molecular docking methodology, preventing reproducibility and validation (R1-M3).
    - Errors in the definitions of variables in the viscometry section (R1-m1).

## Risk / unsupported claims
- The claim that SC 1 is a "less toxic and more effective as an anticancer agent" compared to cisplatin is unsupported due to lack of statistical analysis and limited testing (only one normal cell line).
- The claim of a "robust three-dimensional network" is supported by the crystallographic data, but the functional significance of this network for biological activity is speculative.
- The statement that the docking results "correlate well with the experimental data" is a qualitative assertion without quantitative backing.
- The assignment of the 350 nm emission band to MLCT is not fully supported by the presented data.
- The claim that the complex has "high binding affinity for CT DNA" based on a single Kb value without error is weakly supported.